Open AccessThe HeartMate 6
Author(s) -
Mani A. Daneshmand,
Muath Bishawi,
Carmelo A. Milano,
Jacob N. Schroder
Publication year - 2020
Publication title -
asaio journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.961
H-Index - 66
eISSN - 1538-943X
pISSN - 1058-2916
DOI - 10.1097/mat.0000000000001011
Subject(s) - maglev , artificial heart , bridge to transplantation , bridge (graph theory) , medicine , destination therapy , ventricular assist device , continuous flow , heart transplantation , transplantation , cardiology , intensive care medicine , heart failure , surgery , engineering , electrical engineering , biochemical engineering
The need for biventricular support poses significant challenges for patients who require a mechanical bridge to transplantation. Recent improvements in ventricular assist device (VAD) technology has made possible the use of two centrifugal flow VADs as a total artificial heart (TAH) replacement. The HeartMate 3 (HM3; [Full MagLev, Abbott Laboratories, Chicago, Illinois]) was recently approved as a destination therapy; this VAD has a number of unique advantages that allow for its off-label use for biventricular support. Here, we describe the use of two HM3s as a TAH in a patient as a bridge to transplant.